Sanofi transfers 20 mature drugs, three plants to Cheplapharm for 26.4% stake
SNY•Guidance unchanged
Sanofi expects no change to its 2026 financial guidance.
Equity stake and expected timing
Sanofi will receive a 26.4% equity stake in Cheplapharm as consideration for the portfolio and site transfers.
Commercial handover is slated to start in Q1 2027; the transaction is expected to complete in Q3 2027.
Sanofi to transfer mature medicines and plants to Cheplapharm
Sanofi plans to transfer 20 mature medicines, including Lovenox/Clexane outside the US, to Cheplapharm under a new partnership.
Three manufacturing sites are set to move to Cheplapharm: Csanyikvölgy, Hungary; Jurong, Singapore; Ploërmel, France.
